These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 14648016)

  • 1. Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer.
    Turner PK; Houghton JA; Petak I; Tillman DM; Douglas L; Schwartzberg L; Billups CA; Panetta JC; Stewart CF
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):253-60. PubMed ID: 14648016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin.
    Schwartzberg LS; Petak I; Stewart C; Turner PK; Ashley J; Tillman DM; Douglas L; Tan M; Billups C; Mihalik R; Weir A; Tauer K; Shope S; Houghton JA
    Clin Cancer Res; 2002 Aug; 8(8):2488-98. PubMed ID: 12171874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-gamma-induced sensitization of colon carcinomas to ZD9331 targets caspases, downstream of Fas, independent of mitochondrial signaling and the inhibitor of apoptosis survivin.
    Geller J; Petak I; Szucs KS; Nagy K; Tillman DM; Houghton JA
    Clin Cancer Res; 2003 Dec; 9(17):6504-15. PubMed ID: 14695155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells.
    Tillman DM; Petak I; Houghton JA
    Clin Cancer Res; 1999 Feb; 5(2):425-30. PubMed ID: 10037193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.
    Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J
    Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic correlations of cyclosporine therapy in stable renal transplant patients: evaluation of long-term target C(2).
    Brunet M; Campistol JM; Millán O; Vidal E; Esforzado N; Rojo I; Jiménez O; Oppenheimer F; Corbella J; Martorell J
    Int Immunopharmacol; 2003 Jul; 3(7):987-99. PubMed ID: 12810356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-alpha and interferon-gamma sensitize human tenon fibroblasts to mitomycin-C.
    Wang XY; Crowston JG; Zoellner H; Healey PR
    Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3655-61. PubMed ID: 17652735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
    Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.
    Di Paolo A; Lencioni M; Amatori F; Di Donato S; Bocci G; Orlandini C; Lastella M; Federici F; Iannopollo M; Falcone A; Ricci S; Del Tacca M; Danesi R
    Clin Cancer Res; 2008 May; 14(9):2749-55. PubMed ID: 18451241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effectors of killer activity induced by interferon-alpha and gamma in peripheral blood mononuclear cells.
    Sakaguchi M; Kubota S; Nishikido M; Taniguchi K; Inuzuka S; Saito Y; Kanetake H; Koga S
    Int J Mol Med; 2002 Sep; 10(3):317-20. PubMed ID: 12165807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
    Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha family.
    Masci P; Olencki T; Wood L; Rybicki L; Jacobs B; Williams B; Faber P; Bukowski R; Tong K; Borden EC
    Clin Pharmacol Ther; 2007 Mar; 81(3):354-61. PubMed ID: 17339865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M; Tempero K; Kirby M; Thompson J
    Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-gamma sensitizes osteosarcoma cells to Fas-induced apoptosis by up-regulating Fas receptors and caspase-8.
    Inaba H; Glibetic M; Buck S; Ravindranath Y; Kaplan J
    Pediatr Blood Cancer; 2004 Dec; 43(7):729-36. PubMed ID: 15390286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic study of IST-622, a novel synthetic derivative of chartreusin, by oral administration in a phase II study of patients with breast cancer.
    Asai G; Yamamoto N; Toi M; Shin E; Nishiyama K; Sekine T; Nomura Y; Takashima S; Kimura M; Tominaga T
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):468-72. PubMed ID: 12107551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolic acid inhibits SLE-associated cytokine expression and promotes apoptosis of peripheral blood mononuclear cells from patients with systemic lupus erythematosus.
    Su DL; Wang HJ; Ji XH; Li YY; Xuan HB; Heng C; Li YF
    Acta Pharmacol Sin; 2006 Aug; 27(8):1051-7. PubMed ID: 16867258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer.
    Kho Y; Jansman FG; Prins NH; Neef C; Brouwers JR
    Ther Drug Monit; 2006 Apr; 28(2):206-11. PubMed ID: 16628132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer.
    Nadal C; Maurel J; Gallego R; Castells A; Longarón R; Marmol M; Sanz S; Molina R; Martin-Richard M; Gascón P
    Clin Cancer Res; 2005 Jul; 11(13):4770-4. PubMed ID: 16000573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro.
    Nakamura M; Nagano H; Sakon M; Yamamoto T; Ota H; Wada H; Damdinsuren B; Noda T; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Nakamori S; Dono K; Monden M
    J Hepatol; 2007 Jan; 46(1):77-88. PubMed ID: 17045692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.